Curaleaf Holdings’ fair value estimate has inched up to about C$4.81 per share from roughly C$4.75, driven largely by a slightly more upbeat outlook for revenue growth from around 5.98% to ...
Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results